Evaluation of Response of Dasatinib to Treat Mastocytosis

Summary

This is a multicenter, open-label, single arm phase II non-randomized study of dasatinib in which subjects with systemic mastocytosis (SM) will be treated with a continuous regimen of dasatinib. Upon completion of a treatment induction period, subjects will be treated with dasatinib at a dose of 100 mg per os (OS) once daily (QD).

Timeline

Start

2009-11

Primary completion

2011-12

Completion

2012-12

Drugs

Indications